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Abstract
Hydroxylation is a novel protein modification catalyzed by a family of oxygenases that depend on fundamental nutrients and 
metabolites for activity. Protein hydroxylases have been implicated in a variety of key cellular processes that play important 
roles in both normal homeostasis and pathogenesis. Here, in this review, we summarize the current literature on a highly 
conserved sub-family of oxygenases that catalyze protein histidyl hydroxylation. We discuss the evidence supporting the 
biochemical assignment of these emerging enzymes as ribosomal protein hydroxylases, and provide an overview of their 
role in immunology, bone development, and cancer.
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Abbreviations
2OG  2-Oxoglutarate
MINA  Myc-induced nuclear antigen
NO66  Nucleolar protein 66 kilodalton
HIF  Hypoxia-inducible factor
FIH  Factor-inhibiting HIF
DSBH  Double-stranded beta helix
JmjC  Jumonji-C
RIOX  Ribosomal oxygenase
KDM  Histone lysine demethylase
Introduction
Post-translational modification (PTM) is a major level of 
protein control that plays critical roles in all fundamental 
cellular processes. Our understanding of the proteomic 
landscape of PTMs and the discovery of new protein modi-
fications has been partly fuelled by the development of 
mass-based detection, sequencing and quantification tech-
nologies. Mass spectrometry has revolutionized the ability 
to research small and difficult-to-detect PTMs. One such 
PTM is ‘hydroxylation’, the enzymatic incorporation of a 
single oxygen atom to create an alcohol, or hydroxyl, group. 
Although hydroxylation was once considered to be a very 
rare PTM [1], it is now appreciated to be an important modi-
fication that deserves more scrutiny for its roles in biology 
and for its potential medical applications [2].
Protein hydroxylation is generally catalyzed by a family 
of ‘2-Oxoglutarate (2OG)-dependent oxygenases’ (2OG-
oxygenases) (see below). These enzymes utilize fundamental 
nutrients to catalyze oxidative modifications to a variety of 
biological molecules in addition to protein including DNA, 
RNA and lipid [3, 4]. They target their substrates with simi-
lar levels of specificity as other signaling enzymes: Protein 
hydroxylases generally modify a single residue in a limited 
number of substrates. Thus far, the types of amino acids 
targeted for hydroxylation include prolyl, lysyl, asparaginyl, 
arginyl, aspartyl, and histidyl residues [5–12]. Whilst our 
understanding of prolyl, lysyl and asparaginyl hydroxylation 
has been driven by extensive research into their roles in col-
lagen synthesis and hypoxia signaling [7, 10], the biological 
roles of the other types of protein hydroxylation are less 
well understood. That being said, it is clear that even poorly 
characterized hydroxylases are involved in diverse aspects 
of physiology and in important disease processes [13, 14]. 
In this article, we focus on summarizing our current under-
standing of protein histidyl hydroxylation, the main enzymes 
responsible for catalyzing this novel PTM, and their emerg-
ing roles in cell biology, physiology and disease.
Histidyl hydroxylation was first characterized in 2011, 
with the discovery that factor-inhibiting HIF (FIH), the 
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primary activity of which is asparaginyl hydroxylation, 
can also catalyze site-specific histidyl hydroxylation in the 
ankyrin repeat domain of over-expressed Tankyrase-2 [12]. 
Whether this modification occurs in endogenous Tanky-
rase-2, and whether it has a physiological role in regulating 
Tankyrase-2 function, remains unclear. More recently, two 
closely related 2OG-oxygenases, Myc-induced nuclear anti-
gen (MINA) and nucleolar protein 66 (NO66), were reported 
to hydroxylate specific histidyl residues in endogenous ribo-
somal proteins [6]. Therefore, we focus our attention here on 
MINA and NO66. First, we provide a general background to 
the wider family of 2OG-oxygenases.
2OG‑oxygenases
FIH, MINA and NO66 belong to a gene family of approxi-
mately sixty 2OG-oxygenases. These enzymes catalyze 
various oxidative modifications, including hydroxylation 
and demethylation (via a hydroxylation reaction) (Fig. 1a), 
through the action of a common catalytic domain known 
as a ‘double-stranded beta helix’ (DSBH) [15, 16]. This 
domain consists of eight anti-parallel beta strands which 
together form a barrel-like or ‘cupin’ fold. This structure 
ensures the integration of essential co-factors includ-
ing Fe-(II), the Krebs cycle intermediate 2OG, molecular 
oxygen, and the substrate (Fig. 1b) [15, 16]. A conserved 
‘2-His/1-Carboxylate’ motif mediates Fe-(II)-binding, whilst 
the 2OG-binding residues vary across different sub-families.
Catalysis by 2OG-oxygenases initially proceeds via for-
mation of a highly reactive iron (IV)-oxo intermediate (by 
the oxidative decarboxylation of 2OG), which oxidizes the 
target substrate (Fig. 1b) [15, 16]. Where a 2OG-oxygenase 
has a demethylase function, the product formed is an unsta-
ble hydroxy-methyl group, which spontaneously fragments 
producing formaldehyde and the demethylated substrate 
(Fig. 1a) [13, 17]. The requirement for fundamental nutrients 
and metabolites means that the activity of these enzymes has 
the potential to be regulated by changes in the intracellular 
and extracellular micro-environment. Low tissue oxygen ten-
sions and dysregulation of the Krebs’ cycle have been impli-
cated as important regulators of 2OG-oxygenase function in 
physiological and disease processes [18, 19]. For example, 
increased concentrations of the metabolites succinate and 
fumarate have been shown to competitively inhibit some 
2OG-oxygenases [19, 20], and oxygen limitation inhibits 
hydroxylases that control the proteasomal degradation of 
the hypoxia-inducible transcription factor HIF [7, 18, 21]. 
The catalysis of hydroxylation and demethylation by 2OG-
oxygenases is described in depth in a number of excellent 
reviews [2–4, 13, 15–17].
2OG-oxygenases have been implicated in several funda-
mental cellular processes [4, 14]. Thus, it is perhaps unsur-
prising that 2OG-oxygenases have been linked with a vari-
ety of diseases. These include obesity, cardiovascular and 
pulmonary disease, neurological abnormalities and cancer 
[14, 22]. This in turn has stimulated efforts to understand 
the biochemical activities and cellular functions of 2OG-
oxygenases. Indeed, histidyl hydroxylases were initially 
characterized in disease models, sparking efforts to identify 
and characterize their substrates and biological functions.
Initial discovery and characterization 
of histidyl hydroxylases
MINA and NO66 belong to a subgroup of 2OG-oxygenases 
whose DSBH has homology to that of ‘Jumonji’, a protein 
originally named after the cruciform phenotype observed 
in the corresponding knockout mouse [23]. These DSBH 
domains, now termed Jumonji-C (JmjC) are present in 2OG-
oxygenases that (generally) catalyze protein hydroxylation. 
The largest phylogenetic group of JmjC hydroxylases cata-
lyze lysyl demethylation of histones and have attracted sig-
nificant interest for their roles in epigenetics [17]. In addition 
to the JmjC domain, these proteins also contain functional 
motifs involved in chromatin biology including ARID, Tudor 
and zinc finger domains [13].
In contrast, MINA and NO66 belong to a phylogenetically 
distinct group of JmjC 2OG-oxygenases that do not contain 
Fig. 1  Ribosomal histidyl hydroxylation catalyzed by the 2OG-
oxygenases MINA and NO66. a 2OG-oxygenases that target protein 
substrates can catalyze stable hydroxylation (top), or demethylation 
via a hydroxylation reaction (bottom). Demethylation produces the 
unmethylated substrates and formaldehyde (CHOH). Note that only 
demethylation of a mono-methylated amino acid is shown: 2OG-
oxygenase-mediated demethylation is also possible at tri- and di-
methylated residues. b The catalytic cycle of 2OG-oxygenases. For 
clarity, a graphical representation of only the catalytic pocket, not 
the whole DSBH domain, is shown. c The JmjC-only family of 2OG-
oxygenases. Phylogenetic tree constructed using iTOL online soft-
ware [80] in unrooted tree format using tree data derived from Clustal 
Omega alignment of the following human protein sequences; MINA 
(Q8IUF8), NO66 (Q9H6W3), JMJD4 (Q9H9V9), JMJD5 (Q8N371), 
JMJD6 (Q6NYC1), JMJD7 (POC870), JMJD8 (Q96S16), TYW5 
(A2RUC4), FIH (HIF1AN; Q9NWT6) and HSPBAP1 (Q96EW2). 
Primary biochemical specificities are indicated by His (histidyl 
hydroxylase), Lys (lysyl hydroxylase), Arg (arginyl hydroxylase), Asn 
(asparaginyl hydroxylase), yW-72 (hydroxylase of modified Wybu-
tosine nucleoside in tRNAPhe) or ‘?’ (unknown) [6, 9, 11, 81–83]. 
d Ribosomal oxygenases target important functional domains within 
the ribosome. MINA targets His-39 of Rpl27a within the large (60S) 
subunit, which is located close to the ‘E’-site, the binding site of the 
exiting tRNA. NO66 targets His-216 of the 60S subunit protein Rpl8, 
which is proximal to the peptidyl transferase centre (PTC). The PTC 
binds to the P- and A-site tRNAs and catalyzes peptide bond forma-
tion. e The histidyl residues hydroxylated by MINA and NO66 are 
highly conserved. f MINA and NO66 catalyze beta histidyl hydrox-
ylation. NMR studies indicate that hydroxylation occurs on the beta 
carbon [6]
◂
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other immediately obvious functional domains, particularly 
those recognized as having important roles in chromatin 
biology (see below). As such, this family has been termed 
the ‘JmjC-only’ 2OG-oxygenase sub-family [17]. There 
are ten currently identified JmjC-only 2OG-oxygenases in 
humans (MINA, NO66, JMJD4-8, FIH, TYW5, HSPBAP1 
(Fig. 1c), the majority of which are known or predicted pro-
tein hydroxylases [4, 13].
MINA was first described in 2002 as a c-myc target gene 
following gene expression profiling in HL60 cells that con-
ditionally expressed c-myc [24]. Although MINA appears to 
be ubiquitous [25], its expression does not always correlate 
with myc levels [26], indicating that other factors also likely 
contribute. Indeed, SMAD and Sp1 transcription factors 
have also been identified as regulators of MINA transcrip-
tion [27]. Consistent with its regulation by growth-respon-
sive transcription factors, MINA levels are induced by mito-
gens [24], and it is highly expressed in rapidly proliferating 
tissues such as the testes [28]. Interestingly, MINA levels 
may also be under the control of stress signaling pathways: 
Independent gene expression profiling experiments discov-
ered MINA as a gene whose transcription was induced by 
silica treatment in a Jun kinase-dependent manner (resulting 
in the label ‘mineral dust-induced gene’, or Mdig) [29, 30].
Proteomic analyses of nucleoli purified from Xenopus 
laevis oocytes also led to the discovery of MINA as a novel 
nucleolar protein [26]. Eilbracht et al. reported that MINA 
was localized to the granular component of the nucleoli, a 
sub-compartment normally associated with late stages of 
ribosomal biogenesis. Indeed, mass spectrometry analysis 
of MINA complexes supported its interaction with pre-
ribosomal particles [6]. This led to the proposal that MINA 
may play a role in ribosome biogenesis. Although MINA 
is enriched in the nucleolus, it is also partially localized to 
the nucleoplasm [26, 31]. Whether its differential localiza-
tion reflects multiple cellular functions is unclear, but could 
be consistent with proposed roles in chromatin biology and 
transcription (see below).
Interestingly, the biochemical exploration of the nucleo-
lus that discovered MINA also identified a related JmjC-only 
protein called NO66 [32]. Like MINA, NO66 is also highly 
conserved through evolution and is ubiquitously expressed 
[32]. Furthermore, sucrose-gradient experiments demon-
strated that NO66 co-fractionates with pre-ribosomal par-
ticles, again suggestive of a role in ribosome biogenesis. 
However, additional localization in nucleoplasmic dots that 
colocalize with Ki-67, HP1α and PCNA, suggested that 
NO66 may also have functions in late replicating chromatin 
[32]. Similar to MINA, these observations may be consist-
ent with independent reports of NO66 controlling chroma-
tin modifications and transcriptional regulation (see below). 
Indeed, NO66 was independently identified as a member 
of the myc transcriptional complex and named ‘MAPJD’: 
Suzuki et al. suggested that transactivation of myc by NO66 
could lead to upregulation of genes involved in oncogene 
signaling and the TGFβ pathway [33].
Overall, the studies outlined above suggested that MINA 
and NO66 are ubiquitously expressed proteins that have 
functions in ribosome biogenesis and/or protein transla-
tion, and possibly extra-nucleolar functions in genome 
biology. However, the molecular mechanisms involved in 
these processes remained unclear, partly because of a lack of 
understanding regarding the biochemical activities of these 
enzymes.
Assigning the biochemical activity of MINA 
and NO66
Early studies on MINA and NO66 successfully identified the 
presence of the JmjC domain [24, 26, 32]. Although it was 
not recognized as catalyzing histone lysine demethylation 
at that time, the JmjC domain had been proposed to have 
a role in chromatin remodeling [34, 35]. Subsequently, the 
assignment of histone lysine demethylase (‘KDM’) activity 
to some JmjC domains [17] led investigators to test whether 
MINA and NO66 regulate the methylation status of histone 
lysine marks. Candidate approaches screened the expres-
sion levels of these marks in cells overexpressing MINA or 
NO66, and led to the assignment of both as KDMs [36, 37], 
as outlined below.
Lu et al. noted an inverse correlation between MINA and 
global H3K9me3 levels in lung cancers, and reported that 
manipulating MINA levels by overexpression or RNA inter-
ference caused the anticipated changes in H3K9me3 expres-
sion in bronchial epithelial cells [36]. However, a subsequent 
study by the same group noted marginal effects of MINA on 
H3K9me3 levels in A549 cells [38]. Interestingly, Chen and 
colleagues observed that MINA upregulates the expression 
of KDM4A (a JmjC H3K9me3 demethylase of the KDM 
family) which they proposed may contribute to the observed 
regulation of H3K9me3.
A proteomic analysis of Osterix, an osteoblast-specific 
transcription factor (see below), led to the identification of 
NO66 as an Osterix repressor [37]. Sinha et al. reported 
that NO66 regulates Osterix-specific target promoters and 
proposed that the molecular mechanism involved an unusual 
H3K4 and H3K36 demethylase activity. Chromatin immu-
noprecipitation experiments indicated that the chromatin 
localization of NO66 inversely correlates with H3K4me3 
and H3K36me3 levels [39, 40], suggesting that NO66 may 
regulate the abundance of these epigenetic marks.
Independent, unbiased proteomic screens subsequently 
identified a distinct biochemical activity for both MINA 
and NO66. Mass spectrometry analyses of the MINA and 
NO66 interactomes identified a large number of ribosomal 
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and nucleolar proteins [6], consistent with the work of Eil-
bracht et al. [26, 32]. Synthetic peptides spanning all these 
interacting proteins were tested for a +16 Da shift by mass 
spectrometry, indicative of hydroxylation. These biochemi-
cal assays led to the discovery that MINA efficiently targets 
His-39 of the large ribosomal subunit Rpl27a, and that NO66 
is equally effective at modifying His-216 of Rpl8 (Fig. 1d, 
e) (Rpl27a and Rpl8 are respectively known as uL15 and 
uL2 under the current naming convention). A subsequent 
study by an independent group confirmed Rpl8 His-216 
hydroxylation by NO66 in vitro [41]. NMR studies con-
firmed the biochemical assignment and demonstrated that 
these enzymes hydroxylate at the beta position of the side 
chain (Fig. 1f) [6]. Endogenous Rpl27a and Rpl8 hydroxy-
lation were dependent on MINA and NO66, respectively, 
and (importantly), this occurred in a non-redundant fashion. 
Interestingly, the occupancy of histidyl hydroxylation was 
extremely high in all healthy cell lines and tissues tested 
(> 90%), which may suggest a positive role in ribosome bio-
genesis and/or translation. Structural analyses indicated that 
Rpl27a His-39 is proximal to the ribosomal E-site tRNA, 
and His-216 of Rpl8 is close to the peptidyl transferase 
center (PTC) (Fig. 1d) [42]. Subsequent chemical footprint-
ing analyses of differentially hydroxylated Rpl8 indicated 
that the NO66 hydroxylation reaction likely serves to prop-
erly orientate the 28S rRNA in the vicinity of the PTC, thus 
ensuring appropriate organization of the PTC in the assem-
bled ribosome [42]. The assignment of ‘ribosomal oxyge-
nase’ activity has recently led to NO66 and MINA being 
officially named RIOX1 and RIOX2, respectively. Interest-
ingly, the finding that MINA and NO66 are related to YcFD, 
an Escherichia coli JmjC 2OG-oxygenase that catalyzes 
arginyl hydroxylation of the ribosomal protein Rpl16 [6], 
suggests that ribosomal oxygenase activity is very highly 
conserved. The function of MINA, NO66 and YcfD in ribo-
somal protein hydroxylation is consistent with an emerging 
role for JmjC-only enzymes, and the wider 2OG-oxygenase 
family, in protein translation [43].
Are MINA and NO66 ‘bifunctional’ enzymes that pos-
sess both ribosomal oxygenase and KDM activity? A com-
prehensive study began to address this question by screen-
ing the catalytic domains of 15 JmjC enzymes from across 
the 2OG-oxygenase family against a panel of histone H3 
peptides that spanned each methylation status (me1-3) of 
four lysyl residues; H3K4, H3K9, H3K27 and H3K36 [44]. 
These sites included the proposed demethylation targets of 
both MINA and NO66. Under conditions in which JmjC 
enzymes of the KDM family catalyzed efficient demeth-
ylation of their reported substrates, MINA and NO66 were 
completely inactive. Importantly, however, under the same 
conditions, MINA and NO66 catalyzed efficient hydroxyla-
tion of Rpl27a and Rpl8 peptides, respectively. Similar find-
ings were independently reported following a focussed study 
on NO66 [41]. These data would suggest that the primary 
activity of MINA and NO66 is histidyl hydroxylation.
The specific biochemical activity of an enzyme can also 
be inferred from detailed structural analysis of its active site. 
Indeed, structural analyses of JmjC KDMs and hydroxylases 
have helped to rationalize differences in their biochemical 
specificities (reviewed in [15]).
Structural analysis of histidyl hydroxylases
To investigate the relationship between JmjC ribosomal 
oxygenases and KDMs, Chowdhury et al. solved the crystal 
structures of MINA, NO66 and YcfD [45]. Consistent with 
predictions from primary sequence analyses, these enzymes 
lacked functional motifs commonly associated with KDMs. 
Interestingly, however, they all contained a conserved helical 
motif immediately C-terminal to the JmjC domain that was 
required for dimerization (Fig. 2). Similar to other JmjC-
only hydroxylases [9, 46], oligomerization appears to be 
required for full RIOX activity [41, 45]. Moreover, MINA, 
NO66 and YcfD also share another C-terminal fold termed 
the winged helix (WH) domain (Fig. 2) [41, 45]. Because of 
the absence of this domain in other 2OG-oxygenases [13] it 
has been proposed that KDMs likely evolved from RIOXs 
following the loss of the WH domain [45]. Although its 
exact function is unclear, the restriction of the WH domain 
to RIOXs would suggest a highly conserved role in ribo-
somal protein hydroxylation. WH domains are generally 
implicated in protein–protein or protein-DNA interactions 
[47]. However, Chowdhury et al. suggest that the overall 
negative charge of this domain in MINA, NO66 and YcfD 
makes direct DNA/RNA-binding unlikely [45]. Therefore, 
it is possible that the WH domain mediates an interaction 
with another protein, perhaps a highly conserved factor that 
targets RIOXs to ribosome biogenesis pathways.
Further evidence supporting that MINA and NO66 are bio-
chemically distinct from KDMs came from detailed structural 
analyses of their active sites and the binding mode of their 
substrates [45]. RIOXs bind their substrates in a conserved 
manner that is similar to related JmjC-only hydroxylases such 
as FIH, with a specific N- to C- directionality with respect to 
the catalytic machinery. Importantly, this differs significantly 
from that of most KDMs, including those considered to be 
phylogenetically more closely related to MINA and NO66 
[45]. Furthermore, there are important differences in how 
deeply the target side chain binds in the catalytic pockets of 
RIOXs versus KDMs. Because JmjC-only protein hydroxy-
lases target a carbon in the middle of the side chain, the target 
residue binds deep within the pocket [45]. In contrast, KDMs 
target the  NƐ-methyl site at the end of the lysyl residue, so their 
target residues penetrate less deeply [15]. Finally, the JmjC 
domains of ribosomal oxygenases also lack two flexible loops 
4098 J. R. Bundred et al.
1 3
within the DSBH that are highly conserved within the KDM 
subfamily and essential for lysyl demethylase activity. These 
loops form important interactions with the methylated lysyl 
side chain to facilitate its accommodation within the active 
site of the enzyme [15].
Overall, the combined phylogenetic, evolutionary, struc-
tural and biochemical data are consistent with the assign-
ment of MINA and NO66 as protein histidyl hydroxylases.
Next, we summarize the current literature describing 
the emerging roles of these histidyl hydroxylases in diverse 
aspects of biology and disease.
NO66 and MINA in physiology and disease
The early studies that led to the discovery and biochemi-
cal characterization of MINA and NO66 involved diverse 
approaches, including enzyme-focussed screens (e.g., 
MINA/NO66 proteomics), function-specific proteomics 
(e.g., Osterix), and differential gene expression profiling 
experiments (e.g. c-myc, silica treatment, and lung cancer). 
This diversity has, in turn, contributed to an expanding lit-
erature on the role of these histidyl hydroxylases in mam-
malian physiology and disease, as reviewed below.
NO66
Previous research has identified two main roles for NO66 
in physiology and disease, namely skeletal bone formation 
and tumorigenesis.
NO66 and skeletal development and ossification
As outlined above, NO66 was detected in a proteomic screen 
aimed at identifying the interactome of Osterix, an osteo-
blast-specific transcription factor that is required for osteo-
blast differentiation and bone formation [37]. Further char-
acterization of this interaction identified that NO66 inhibits 
the ability of Osterix to drive osteoblast-specific gene tran-
scription (Fig.  3a), through an interaction between the 
dimerization domain of NO66 and a defined 16 amino acid 
sequence within the transactivation domain of Osterix [37, 
48]. Overexpression of NO66 is sufficient to suppress the 
transactivation domain of Osterix using in vitro cell mod-
els [37], and mesenchymal-specific overexpression inhibits 
osteoblast proliferation and differentiation, skeletal growth 
and bone formation in mice [49]. Conversely, mesenchymal-
specific ablation of NO66 increases the expression of genes 
that promote bone growth and development in mice, with a 
consequent increase in bone mass and density [50].
Importantly, overexpression experiments in HEK293T 
cells suggested that the ability of NO66 to repress the trans-
activation domain of Osterix is dependent on its enzymatic 
activity [37]. Although de Crombrugghe and colleagues sug-
gest that NO66 regulates Osterix target genes via an intrin-
sic histone demethylase activity [37, 40], this may require 
further consideration, for reasons outlined above [15, 41, 
44, 45]. Interestingly, other work suggests that NO66 exists 
in complexes containing important epigenetic modifiers 
including DNA methyltransferase 1A (DNMT1A), histone 
Fig. 2  Domain organization of 
ribosomal oxygenases. Reported 
crystal structures indicate 
a unique topology for JmjC 
ribosomal oxygenases that is 
conserved from Homo sapiens 
(Hs) to prokaryotes (includ-
ing R. marinus, Rm). Note that 
YcfD catalyzes arginyl hydroxy-
lation of Rpl16 in prokaryotes 
[6]. Critical catalytic residues 
are indicated. The dimeriza-
tion domain is required for 
oligomerization and activity 
[45]. The function of the WH 
domain is unclear but, because 
of its overall negative charge, 
is thought unlikely to mediate 
an interaction with nucleic acid 
[45]
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deacetylase 1A (HDAC1A), HP1 and PRC2 (Fig. 3a) [39, 
40], raising the possibility that NO66 might regulate his-
tone methylation status and target gene expression via an 
intermediary.
Whilst the molecular mechanism by which NO66 influ-
ences bone formation in vivo and osteoblast differentiation 
in vitro remains unclear (Fig. 3a), it is evident that NO66 is 
an important regulator of bone growth and mineralization (a 
mechanistic discussion of the roles of NO66 (and MINA) is 
presented at the end of this review). Considering the poten-
tial implications for diseases such as osteoporosis and osteo-
penia [51], further research in this area is warranted.
NO66 and cancer
2OG-oxygenases are attracting significant academic and 
pharmaceutical interest for their roles in tumor develop-
ment and metastasis [14]. These roles are diverse and 
include, but are not limited to, cellular dedifferentiation 
via histone demethylation, hypoxia sensing in tumors, 
and regulation of inflammation and resistance to apop-
tosis [13, 14, 18]. In addition to aberrant expression and 
genetic alteration, 2OG-oxygenases may be deregulated 
by additional mechanisms in cancer, including competi-
tive inhibition by ‘onco-metabolites’ (e.g., fumarate, see 
Introduction), and by low oxygen tensions in poorly vascu-
larized areas of the tumor [13, 18–20]. Although it is cur-
rently unclear whether such mechanisms regulate MINA 
and NO66 activity in tumors, there is some evidence sug-
gesting that ribosomal hydroxylation may be reduced in 
severe hypoxia. Ribosomal oxygenases are some of the 
only 2OG-oxygenases downregulated at the transcriptional 
level during hypoxia [52]. Indeed, reduced NO66 protein 
expression under severe hypoxia correlated with impaired 
Rpl8 hydroxylation [6]. Whether this effect was primarily 
due to reduced enzyme abundance, and/or a direct effect 
on enzyme activity remains unclear. Furthermore, it is 
not yet known whether MINA and NO66 ‘sense’ oxygen 
Fig. 3  NO66 is implicated in skeletal development and tumorigen-
esis. a NO66 represses the osteoblast-specific transcription factor 
Osterix (Osx). Osterix drives the transcription of specific target genes 
(e.g., Col1a1) to promote osteoblast differentiation and bone develop-
ment. The dimerization domain of NO66 interacts with the transacti-
vation domain of Osx, leading to reduced Osx target gene expression. 
Whether this involves a direct effect of an NO66 histone demethylase 
activity, or results from the recruitment of multiple epigenetic modi-
fiers (e.g., PRC2, HP1, etc.), is currently unclear (signified by ‘?’). b 
NO66 is over-expressed in lung and colorectal cancers and promotes 
tumor cell growth and invasion in vitro. Whether the enzymatic activ-
ity of NO66 is involved is unclear (‘-OH?’). The molecular mecha-
nisms involved are also unknown, but could be related to roles in 
myc-driven transcriptional control (left) and/or ribosome biogenesis/
translation (right). HDAC1A histone deacetylase 1A; PRC2 polycomb 
repressor complex 2; HP1 heterochromatin protein 1; DNMT1A DNA 
methyltransferase 1A; Col1a1 collagen type I alpha 1 chain; Bsp bone 
sialoprotein; Oc osteocalcin; HAT histone acetyltransferase complex 
(TRRAP and TIP60)
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in the physiological range in a manner akin to the HIF 
hydroxylases, and whether such effects are relevant to 
tumor biology. That being said, there is mounting evidence 
supporting the role of both enzymes in cellular processes 
implicated in cancer.
The first indication that NO66 may have a role in cancer 
followed comparative gene expression profiling in normal 
versus non-small cell lung cancer (NSCLC) [33]. Suzuki 
et al. identified NO66 mRNA as frequently over-expressed 
in the majority of NSCLC samples and lung cancer cell 
lines tested. Overexpression of NO66 conferred increased 
growth potential upon NIH3T3 fibroblasts, whilst RNA 
interference in LC319 and A549 lung cancer cells reduced 
growth. Of interest with respect to the function of NO66 in 
transcriptional regulation, and the potential role of MINA 
downstream of Myc, Suzuki et al. also characterized tran-
scriptional activation mediated by a complex containing 
NO66, Myc and histone acetyltransferases (Fig. 3b) [33].
In addition to the cell biology approaches outlined above, 
pathology analyses have investigated the expression of NO66 
in human tumor samples. High levels of NO66 in colorectal 
cancer samples were associated with metastatic potential, 
venous invasion and lymph node metastasis: Patients whose 
tumors stained positively for NO66 had significantly shorter 
survival and disease-free survival [53]. Similar to the work 
in lung cancer cell lines described above, overexpression of 
NO66 in colorectal cells was also sufficient to promote their 
growth, and their invasion (Fig. 3b).
The mechanism(s) by which NO66 promotes tumor 
cell growth and invasion remains unclear. Further work 
is required to determine the relative contribution of Rpl8 
hydroxylation versus other potential functions in gene 
expression control and epigenetics (discussed in more detail 
below).
MINA
MINA has generally been studied in more detail than NO66 
and is implicated in a wider range of physiological and path-
ological processes, particularly those related to the immune 
system and cancer.
MINA and cancer
The identification of MINA as target of the myc proto-onco-
gene (see above) led to pathology studies aimed at detecting 
its protein expression in a range of tumor types by immu-
nohistochemistry. There are now several reports describing 
MINA overexpression in multiple cancer types including 
colorectal [54], lung [30, 55], esophageal [56], lymphoma 
[57], cholangiocarcinoma [58], gingival squamous cell car-
cinoma [59], neuroblastoma [60], liver [61, 62], gastric [63], 
pancreatic [64], multiple myeloma [65], and breast cancers 
[66]. Importantly, MINA expression was associated with 
poor prognosis in some, but not all, of these studies [56, 60, 
63, 65–67]. Interestingly, MINA overexpression positively 
correlated with immunohistochemical markers of prolifera-
tion in several studies [58–60, 62, 67]. These observations, 
in combination with MINA being a growth-responsive gene 
(see above) [24], led to the proposal that MINA may sup-
port tumorigenesis by promoting cancer cell proliferation. 
Indeed, cell biology studies have confirmed that blocking 
MINA expression (using RNA interference) limits the pro-
liferative capacity of several tumor cell lines in vitro [24, 
54, 56, 61, 64, 68]. Together, these data would indicate that 
MINA expression supports the proliferative drive of tumor 
cells (Fig. 4a), at least in some contexts.
Recent work suggests that the role of MINA in cancer 
may be more complex than first thought, however. Specifi-
cally, MINA overexpression may not always correlate with 
poor patient prognosis. Although MINA overexpression 
was associated with worse survival in lung cancer patients 
who were staged ‘lymph node negative’ (N0) or ‘possible 
proximal lymph node metastasis’ (N1) (consistent with the 
cancer ‘driver’ work reviewed above), MINA expression was 
associated with improved prognosis in patients with distant 
lymph node invasion (N2) or ‘distant metastasis likely’ (M1) 
[31]. This observation might suggest that MINA has oppos-
ing roles at different stages of tumorigenesis, with a growth-
promoting role in early cancer, and a tumor suppressor role 
in later stage disease, possibly via modulating invasion and/
or metastasis (Fig. 4a). Perhaps consistent with the latter, 
overexpression of MINA suppressed the migration and 
invasion of A549 and H226B lung cancer cells in vitro [31, 
69]. Conversely, MINA knockdown enhanced their invasion 
and migration [31, 69], and in a manner that was associated 
with changes in markers of epithelial–mesenchymal transi-
tion [70].
Importantly, the complex association of MINA expres-
sion with prognosis may not be restricted to lung cancer. 
Breast cancer patients without lymph node involvement 
are reported to have worse survival if their tumors express 
higher levels of MINA, whereas MINA expression is associ-
ated with improved survival of patients that are lymph node 
positive [66]. This, together with the studies outlined above, 
might suggest that MINA can have a tumor suppressor func-
tion in some contexts, possibly via the control of invasion 
and migration. However, it remains unclear whether MINA 
is a bona fide tumor suppressor gene, and if so, what the 
molecular mechanisms involved might be (Fig. 4a) (further 
discussed below).
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MINA and immunology
The first evidence implicating MINA as an immuno-modu-
lator came from mouse studies in which it was identified as a 
genetic determinant of ‘T-helper type 2  (TH2) bias’ [71], the 
tendency of naive  CD4+ T cells to differentiate into IL4-pro-
ducing  TH2 cells.  TH2 bias is an important immunological 
process that regulates susceptibility to autoimmune, allergic, 
and infectious disease [72]. Okamoto et al. reported that 
MINA modulates  TH2 bias by acting as a direct repressor of 
IL-4 transcription (Fig. 4b) [71].
An independent study subsequently implicated MINA in 
controlling the balance between additional T cell sub-types, 
specifically Th17 and Treg cells [73]. Th17 cells are pro-
inflammatory IL17-producing T-cells that have important 
roles in protecting against extracellular pathogens, and in 
the onset of autoimmune diseases [74]. Yosef et al. under-
took a temporal analysis to identify the dynamic regulatory 
gene expression network involved in Th17 differentiation, 
and studied the role of novel targets in these networks using 
nanowire-based siRNA delivery [73]. This approach iden-
tified that MINA mRNA is strongly induced during Th17 
differentiation, and that MINA promotes the expression of 
Th17 factors such as ROR-γt, Batf, and Irf4, whilst suppress-
ing the expression of the Foxp3 transcription factor, which 
plays a pivotal role Treg in biology (Fig. 4b).
The two studies outlined above suggested, for the first 
time, that MINA has potentially important roles in regu-
lating T-cell differentiation, and that it might, therefore, 
be involved in the etiology of some autoimmune, allergic, 
and infectious diseases. Indeed, recent evidence implicates 
MINA in asthma and pulmonary fibrosis. A case–control 
study in a Han-Chinese population identified a single-
nucleotide polymorphism (SNP) of the MINA gene that 
was associated with a significant increase in the risk of 
atopic asthma, and that patients heterozygous for this allele 
had elevated serum levels of IgE and IL-4 (the effect on 
MINA expression was not reported) [75]. Interestingly, a 
recent study using a mouse model of asthma induced by 
house dust mite aeroallergens found that MINA knockout 
significantly ameliorated airway hyper-responsiveness and 
decreased inflammation [76]. Counter to the role of MINA 
in repressing IL-4 in naive  CD4+ T cells (as above), this 
MINA knockout phenotype was associated with decreased 
levels of IL4. The authors speculated that this may be medi-
ated via an independent role for MINA in promoting  TH2 
Fig. 4  MINA is implicated in tumorigenesis and T-cell differen-
tiation. a MINA is over-expressed in multiple tumor types and is 
required for cancer cell proliferation in vitro. Whether the enzymatic 
activity of MINA is required is unclear, particularly with respect to 
potential roles in gene expression control (‘-OH’?). ‘Driver’ roles 
for MINA in cancer are denoted by red arrows. MINA may also have 
tumor suppressor activity in some contexts, possibly via regulation of 
invasion/metastasis (denoted by blue ‘flat head’ arrows). These par-
adoxical effects were first uncovered by pathology analyses in lung 
and breast cancer (summarized at the bottom). b Immunology: MINA 
regulates the differentiation of specific T-cell subsets in asthma and 
pulmonary fibrosis. MINA represses Interleukin-4 (IL-4) transcrip-
tion to regulate T-helper 2  (TH2) cell bias (top). MINA upregulates 
a T-helper 17  (TH17) differentiation transcriptional program and sup-
presses the expression of the master regulator of regulatory T-cell 
(Treg) differentiation (Foxp3)
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cytokine expression in antigen presenting cells. Others have 
proposed that the reduced airway disease in this model may 
be associated with a defective Th17 response [77]. If cor-
rect, this would suggest that the known role of MINA in 
Th17 differentiation (outlined above) may be dominant with 
respect to its role in  TH2 bias, at least in this particular dis-
ease. This hypothesis may be supported by a recent study in 
which heterozygous knockout of the MINA gene in mice was 
associated with reduced silica-induced pulmonary fibrosis, 
possibly due to an observed decrease in the Th17 response 
(and corresponding increase in the Treg response) [78].
In summary, the finding that MINA influences the bal-
ance between multiple T-cell subsets may be consistent with 
important roles in several T-cell-mediated responses and dis-
eases, including perhaps other pathological contexts such as 
transplant rejection, autoimmunity and infection. The key 
now is to understand the determinants that influence the role 
of MINA in T-cell biases and specific immunological dis-
ease states. In addition, further studies are needed to shed 
light on the molecular mechanisms by which MINA exerts 
its complex effects on the immune system.
What are the molecular mechanisms 
under‑pinning the role of MINA and NO66 
in physiology and disease?
In the preceding sections of this review, we have summa-
rized the current literature on the protein histidyl hydroxy-
lases MINA and NO66, including reports of diverse roles in 
fundamental cellular pathways and important physiological 
and pathological processes. Although the biomedical impor-
tance of these enzymes is becoming increasingly clear, the 
molecular mechanisms involved, and how these might be 
deregulated in disease, have not yet been established. In the 
future it will be important to determine whether the enzy-
matic activity of these 2OG-oxygenases is required for any 
of the functions described. It is possible, for example, that 
non-enzymatic functions may be involved, perhaps medi-
ated via the WH domain. If enzyme activity is required, 
however, it will be of interest to determine how hydroxyla-
tion regulates substrate function to elicit the correspond-
ing biological outcome. It will be worthwhile considering 
whether Rpl27a and Rpl8 modification are likely to solely 
account for the diversity in biological functions reported. If 
histidyl hydroxylation functions in ribosome biogenesis to 
promote increased rates of bulk protein synthesis, it could 
perhaps explain the role of these enzymes in supporting cell 
growth, and the association of their expression with poor 
cancer prognosis (Figs. 3b, 4a). However, it is perhaps more 
difficult to conceptualize how increased ribosome biogenesis 
could elicit biological specificity in terms of transcriptional 
control (e.g., MINA and IL17/Foxp3, Fig. 4b) or physiology 
(e.g., NO66 and bone development, Fig. 3a). Such specificity 
might be more easily rationalized if the function of riboso-
mal protein hydroxylation was to control the translation of 
specific mRNAs, as opposed to bulk ribosome biogenesis. 
The former could, perhaps, be consistent with the localiza-
tion of MINA- and NO66-catalyzed histidyl hydroxylations 
to functionally important sites of the ribosome (Fig. 1d). 
Of course, other explanations are also possible, and these 
may not necessarily be mutually exclusive. An intriguing 
possibility is that other, as yet unidentified substrates exist 
for these protein hydroxylases. Considering the biology 
reviewed above, one might predict that such novel targets 
could have functions in transcription and/or chromatin biol-
ogy/epigenetics (Figs. 3, 4). Thus, further study of the role 
of MINA and NO66 histidyl hydroxylase activity is war-
ranted. Future findings will be critical for not only providing 
mechanistic insight into how these enzymes regulate their 
respective physiological processes and disease, but also for 
determining whether the development of small molecule 
inhibitors is merited. Importantly, competitive inhibitors of 
2OG-oxygenases are in clinical trials for other indications 
[79], suggesting that targeting MINA and/or NO66 is theo-
retically possible. Such inhibitors would likely benefit from 
stringent enzyme specificity considering the role of other 
2OG-oxygenases in fundamental cellular processes [4, 14, 
22]. Bearing in mind the paradoxical roles of MINA in can-
cer (Fig. 4b) [31, 69], the contexts of their potential medical 
applications should also be very carefully considered.
Concluding remarks
Here, we have reviewed our current understanding of 
the role of the histidyl hydroxylases MINA and NO66 in 
cell biology, homeostasis and disease. We hope to have 
highlighted that these enigmatic enzymes have intriguing 
roles in fundamental cellular processes that warrant fur-
ther investigation. In particular, this review emphasizes the 
need for future mechanistic studies that clarify the role of 
hydroxylase activity, and the identity of critical targets, in 
the cellular pathways and diseases discussed. Such work 
will be necessary to build a solid foundation from which 
to efficiently and successfully translate these 2OG-oxyge-
nases into the clinic. Finally, it remains to be seen whether 
the proteome contains hydroxy-histidyl residues depos-
ited by other protein hydroxylases. These could include 
enzymes from novel classes, or perhaps the biochemically 
unassigned members of the JmjC-only family (Fig. 1c). 
It is intriguing to consider the possibility that MINA and 
NO66 might represent the ‘tip of the iceberg’ with respect 
to the biology of histidyl hydroxylation.
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